Skip to main content

Initiative on Optimizing Malaria Vaccine Lab Assays Evaluation

Objective

A broad-range of candidate malaria vaccines derived from diverse novel technologies have resulted from the multiple approaches being taken by different groups in developing malaria vaccines. The majority of the candidates are recombinant proteins based on complex native antigens found on the surface of the parasite. Vaccine potential of these parasite surface antigens is often supported by epidemiological data, and by the ability to induce specific antibodies or potential protective responses in animals and later, in humans. Individual groups have developed assays within the context of the vaccine discovery efforts, with identification of measurable processes for parasite growth and virulence to test specific antigens. In-house assays are strain, stage and even process specific and the ability to compare results between different candidates is further limited by diverse methodologies and assay components such as parasites, cells and reagents. The absence of some level of harmonization of practices also makes interpreting the meaning and relevance of vaccine research outcomes complex. Lack of an enabling environment for comparability of research results generated in different labs could unfortunately lead to scepticism of the results that in turn generate uncertainty about the efficacy of the vaccines and rationale of the development pathway. To compare the relative merits of different candidate vaccines and approaches in a credible and informed manner, efforts must be made to create this enabling environment by supporting the development of a baseline level of standardization around key assays that can be utilized a) in the evaluation of malaria vaccines, and b) throughout the Development process. Consistent, reproducible and comparable intra- and inter-lab performance and increased accuracy and precision of assay data, will strengthen the quality of the data on vaccine performance and generate greater confidence in the vaccine potential of the candidate.

Field of science

  • /medical and health sciences/health sciences/infectious disease/malaria
  • /natural sciences/biological sciences/biochemistry/biomolecules/proteins
  • /medical and health sciences/basic medicine/pharmacology and pharmacy/pharmaceutical drug/vaccines

Call for proposal

FP7-HEALTH-2007-B
See other projects for this call

Funding Scheme

CSA-CA - Coordination (or networking) actions

Coordinator

EUROPEAN VACCINE INITIATIVE EWIV
Address
Vossstrasse 2 Geb 4040
69115 Heidelberg
Germany
Activity type
Research Organisations
EU contribution
€ 294 512,11
Administrative Contact
Odile Leroy (Dr.)

Participants (13)

INSTITUT PASTEUR
France
EU contribution
€ 100 000
Address
Rue Du Docteur Roux 25-28
75724 Paris Cedex 15
Activity type
Research Organisations
Administrative Contact
Nadia Khelef (Dr.)
STICHTING BIOMEDICAL PRIMATE RESEARCH CENTER
Netherlands
EU contribution
€ 55 224
Address
Lange Kleiweg 161
2288 GJ Rijswijk Zh
Activity type
Research Organisations
Administrative Contact
Alan William Thomas (Dr.)
STOCKHOLMS UNIVERSITET

Participation ended

Sweden
Address
Universitetsvagen 10
10691 Stockholm
Activity type
Higher or Secondary Education Establishments
Administrative Contact
Klavs Berzins (Prof.)
THE UNIVERSITY OF EDINBURGH
United Kingdom
EU contribution
€ 135 000
Address
Old College, South Bridge
EH8 9YL Edinburgh
Activity type
Higher or Secondary Education Establishments
Administrative Contact
Angela Noble (Ms.)
THE CHANCELLOR, MASTERS AND SCHOLARS OF THE UNIVERSITY OF OXFORD
United Kingdom
EU contribution
€ 40 794
Address
Wellington Square University Offices
OX1 2JD Oxford
Activity type
Higher or Secondary Education Establishments
Administrative Contact
Gary Strickland (Mr.)
STICHTING KATHOLIEKE UNIVERSITEIT
Netherlands
EU contribution
€ 130 000
Address
Geert Grooteplein Noord 9
6525 EZ Nijmegen
Activity type
Higher or Secondary Education Establishments
Administrative Contact
Wim Bruinenberg (Mr.)
WORLD HEALTH ORGANIZATION
Switzerland
EU contribution
€ 180 000
Address
Avenue Appia 20
1211 Geneve
Activity type
Research Organisations
Administrative Contact
Saladin Osmanov (Dr.)
PATRICE MARTIN DUBOIS - IMMUNOVACC CONSULTING
Belgium
Address
Rue Colonel Chaltin 49
1180 Bruxelles
Activity type
Private for-profit entities (excluding Higher or Secondary Education Establishments)
Administrative Contact
Patrice Dubois (Dr.)
PROGRAM FOR APPROPRIATE TECHNOLOGYIN HEALTH
United States
Address
Leary Way Nw 1455
98107-5136 Seattle Wa
Activity type
Research Organisations
Administrative Contact
Christian Loucq (Dr.)
FUNDACIO CENTRE DE RECERCA EN SALUT INTERNATIONAL DE BARCELONA
Spain
EU contribution
€ 50 000
Address
Calle Villarroel 170
08036 Barcelona
Activity type
Research Organisations
Administrative Contact
Pau Balcells (Mr.)
Public Health England an Executive Agency of the Dept of Health
United Kingdom
Address
Waterloo Road
SE1 8UG London
Activity type
Research Organisations
Administrative Contact
Barry Walker (Dr.)
United States Department of Health and Human Services
United States
Address
Independence Avenue S. W. 200
20201 Washington D.c.
Activity type
Public bodies (excluding Research Organisations and Secondary or Higher Education Establishments)
Administrative Contact
Ya Ping Shi (Dr.)
STATENS SERUM INSTITUT

Participation ended

Denmark
EU contribution
€ 14 469,89
Address
Artillerivej 5
2300 Kobenhavn S
Activity type
Research Organisations
Administrative Contact
Odile Leroy (Dr.)